Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Anticancer Research|May 13, 2015
Class III Beta-tubulin Expression in Non-small Cell Lung Cancer: A Predictive Factor for Paclitaxel ResponseTakuya Ohashi, Tatsuya Yoshimasu, Shoji Oura, et al.
The Journal of Dermatology|September 22, 2011
Examination of the correlation between the manual and automated serological testing methods for syphilisTomohiko Onoe, Mariko Honda, Koma Matsuo, et al.
The Prostate|April 19, 2019
Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequenceMariko Honda, Takahiro Kimura, Yuko Kamata, et al.
Journal of Virology|November 20, 2009
Antibody to varicella-zoster virus immediate-early protein 62 augments allodynia in zoster via brain-derived neurotrophic factorYuka Hama, Kimiyasu Shiraki, Yoshihiro Yoshida, et al.
World Journal of Urology|March 24, 2026
Real-world persistence of vibegron in patients aged ≥ 80 years with overactive bladder: a multicenter cohort studyTaro Igarashi, Yuto Nukariya, Shota Kawano, et al.
Journal of Oral Science|March 27, 2018
Erratum to "Characterizations of oral microbiota in elderly nursing home residents with diabetes"Taiji Ogawa, Mariko Honda-Ogawa, Kazunori Ikebe, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|February 8, 2025
Isepamicin alone as antimicrobial prophylaxis for transrectal prostate needle biopsy: "Do we still need levofloxacin? "Hiroki Yamada, Kojiro Tashiro, Yusuke Takahashi, et al.
Journal of Oral Science|October 11, 2017
Characterizations of oral microbiota in elderly nursing home residents with diabetesTaiji Ogawa, Mariko Honda-Ogawa, Kazunori Ikebe, et al.
Anticancer Research|October 28, 2015
A Theoretical Model for the Hormetic Dose-response Curve for Anticancer AgentsTatsuya Yoshimasu, Takuya Ohashi, Shoji Oura, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 31, 2023
Patients with PSA below 0.2 ng/mL at 8 years post high-dose-rate brachytherapy have an extremely low risk of subsequent recurrenceMinoru Nakazono, Fumihiko Urabe, Kosuke Iwatani, et al.
Pageof 6